ES2751391T3 - Procedimientos de tratamiento de trastornos metabólicos - Google Patents

Procedimientos de tratamiento de trastornos metabólicos Download PDF

Info

Publication number
ES2751391T3
ES2751391T3 ES14768873T ES14768873T ES2751391T3 ES 2751391 T3 ES2751391 T3 ES 2751391T3 ES 14768873 T ES14768873 T ES 14768873T ES 14768873 T ES14768873 T ES 14768873T ES 2751391 T3 ES2751391 T3 ES 2751391T3
Authority
ES
Spain
Prior art keywords
nrg4
protein
seq
metabolic disorder
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14768873T
Other languages
English (en)
Spanish (es)
Inventor
Jiandie Lin
Guoxiao Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Application granted granted Critical
Publication of ES2751391T3 publication Critical patent/ES2751391T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES14768873T 2013-03-21 2014-03-19 Procedimientos de tratamiento de trastornos metabólicos Active ES2751391T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361804046P 2013-03-21 2013-03-21
PCT/US2014/031171 WO2014153385A2 (en) 2013-03-21 2014-03-19 Methods of treating metabolic disorders

Publications (1)

Publication Number Publication Date
ES2751391T3 true ES2751391T3 (es) 2020-03-31

Family

ID=51581794

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14768873T Active ES2751391T3 (es) 2013-03-21 2014-03-19 Procedimientos de tratamiento de trastornos metabólicos

Country Status (6)

Country Link
US (1) US9878010B2 (enExample)
EP (1) EP2976094B1 (enExample)
JP (1) JP6565121B2 (enExample)
CN (1) CN105228641A (enExample)
ES (1) ES2751391T3 (enExample)
WO (1) WO2014153385A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744512B1 (en) 2011-08-15 2019-07-03 Children's Hospital Los Angeles Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis
AU2015336954A1 (en) * 2014-10-22 2017-06-08 Katholieke Universiteit Leuven Ku Leuven Research & Development Modulating adipose tissue and adipogenesis
WO2016116477A1 (en) * 2015-01-20 2016-07-28 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
WO2017058828A1 (en) 2015-09-28 2017-04-06 Children's Hospital Los Angeles Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
WO2020086667A1 (en) * 2018-10-25 2020-04-30 American University Method for promoting adipocyte differentiation and obesity-related disease treatment
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CN110279860A (zh) * 2019-07-31 2019-09-27 上海交通大学医学院附属瑞金医院 Nrg4作为靶点在制备糖尿病药物中的应用
CN114075272B (zh) * 2020-08-10 2023-09-22 杭州俊丰生物工程有限公司 一种人神经调节蛋白4的制备方法
WO2024163874A2 (en) * 2023-02-03 2024-08-08 Avexegen Therapeutics, Inc. Stable and controlled release formulations of neuregulin-4 analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
WO2001014415A2 (en) * 1999-08-20 2001-03-01 Chiron Corporation Egfh2 genes and gene products
US7094882B2 (en) * 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
US6544759B1 (en) * 2000-04-21 2003-04-08 Yeda Research And Development Co. Ltd Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
US7198899B2 (en) * 2002-06-03 2007-04-03 Chiron Corporation Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
US20050005622A1 (en) * 2003-07-10 2005-01-13 Powell Brian C. Condiment holder
US20070015839A1 (en) * 2005-07-14 2007-01-18 Franco Folli Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
ES2315110B1 (es) * 2006-07-14 2009-12-30 Universidad De Barcelona Compuestos para el tratamiento de enfermedades relacionadas con la resistencia a la insulina.
US20100303757A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management

Also Published As

Publication number Publication date
EP2976094B1 (en) 2019-08-28
CN105228641A (zh) 2016-01-06
EP2976094A4 (en) 2016-09-14
US9878010B2 (en) 2018-01-30
EP2976094A2 (en) 2016-01-27
JP6565121B2 (ja) 2019-08-28
WO2014153385A2 (en) 2014-09-25
WO2014153385A3 (en) 2014-11-13
JP2016522163A (ja) 2016-07-28
US20160279201A1 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
ES2751391T3 (es) Procedimientos de tratamiento de trastornos metabólicos
TWI427084B (zh) 穩定化之類胰島素生長因子多肽
Snijders et al. Satellite cells in human skeletal muscle plasticity
KR102166110B1 (ko) 키메라 알칼리성 포스파타제-유사 단백질
ES2750008T3 (es) Células madre mesenquimatosas modificadas genéticamente que expresan klotho
Kim et al. Calcium‐sensing receptor (CaSR) as a novel target for ischemic neuroprotection
Akakabe et al. Ecscr regulates insulin sensitivity and predisposition to obesity by modulating endothelial cell functions
EP3104873B1 (en) Fgf-8 for use in treating diseases or disorders of energy homeostasis
ES2602629T3 (es) Compuestos y métodos para tratar trastornos de los huesos y controlar el peso
Kuefner et al. Secretory phospholipase A2 group IIA enhances the metabolic rate and increases glucose utilization in response to thyroid hormone
CA3178516A1 (en) Methods and compositions for inducing brown adipogenesis
KR20190137786A (ko) 뇌 오스테오칼신 수용체 및 인지 장애
US8383580B2 (en) Methods of administering lipocalins to treat metabolic disorders and cardiovascular diseases
ES3008920T3 (en) Methods for regulating free fatty acid flux using fat specific protein 27 (fsp27) compositions
PT1701978E (pt) Utilização de caderina-t solúvel no tratamento de distúrbios metabólicos
ES2402096T3 (es) Uso de proteínas relacionadas con saposina para prevenir y tratar la obesidad, diabetes y/o síndrome metabólico
JPWO2007139120A1 (ja) アミロイドβクリアランス促進剤
KR20130122927A (ko) Ｄｋｋ2 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 그의 용도
US20250281572A1 (en) Compositions and methods for treating and preventing metabolic disorders
Alliouachene et al. Uninephrectomy and class II PI3K-C2β inactivation synergistically protect against obesity, insulin resistance and liver steatosis in mice
US20250009842A1 (en) Methods for Regulating Muscle Performance using Fat Specific Protein 27 (FSP27) Compositions
JP2013510839A (ja) 治療方法およびスクリーニング方法
US20200009227A1 (en) Compositions and methods of controlling expression of thermogenin (ucp-1) in skeletal muscles
Johnson et al. AAV9 gene therapy restores lifespan and treats pathological and behavioral abnormalities in a mouse model of CLN8-Batten disease
Croteau Direct cardiac actions of Ertugliflozin